Chu Dijon Bourgogne
Dijon, France
NCT Number: NCT05476224
Currently, the world is facing a SARS-CoV2 coronavirus epidemic, which is responsible for COVID-19. In France, this virus has already infected several million people and is responsible for the death of more than 127,000.
Infection is associated with a higher number of cardiovascular events (myocardial infarction, stroke, cardiac arrhythmia, thrombosis ...) in the short and medium term after infection. The long-term complications of this infection are not yet known and are the subject of research in France and in the world.
In order to investigate the possible long term sequelae of this virus infection, this research aims to evaluate the potential cholesterol abnormalities caused by COVID-19, which could play a significant role in the increase of cardiovascular risk in affected patients.
A total of 180 analysable participants will be recruited in this study. They will be divided into four groups of participants that will be compared to one another:
* 30 participants who were infected with SARS-CoV2 with no or few signs and did not require hospitalization. * 30 participants who were infected with SARS-CoV2 and whose severity of illness required hospitalization in a COVID unit * 30 participants who were infected with SARS-CoV2 and required intensive care hospitalization due to severity of illness. * 90 participants who were not infected with SARS-CoV2.
For each participant, the study will last approximately 1 hour, the time to fill out the consent forms, to answer a few questions about their current medical history and finally to take a blood sample for lipid measurements.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Dijon, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants with a history of asymptomatic/mildly symptomatic SARS-CoV2 infection:
Participants with a history of symptomatic SARS-CoV2 infection hospitalized at the Dijon University Hospital excluding the intensive care unit:
Participants with a history of symptomatic SARS-CoV2 infection hospitalized at Dijon University Hospital in the ICU:
Participants with no history of SARS-CoV2 infection:
Exclusion criteria
For all participants:
For participants with a history of asymptomatic/mildly symptomatic SARS-CoV2 infection:
For participants with a history of symptomatic SARS-CoV2 infection hospitalized outside the ICU:
For participants with no history of SARS-CoV2 infection:
Secondary exclusion criteria :
For healthy volunteers with no history of SARS-CoV2 infection:
Positive specific serology for SARS-CoV2 infection at the screening visit.
The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
Time frame: At baseline
Centre Hospitalier Universitaire Dijon
Other
Acronym: COVI-LIPI-D
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05125887
COVID-19, Coronaviridae Infections
Limoges, France
View Trial DetailsNCT04590222
COVID-19, Coronaviridae Infections
Le Kremlin-Bicêtre, France
View Trial DetailsNCT06181292
COVID-19, Coronaviridae Infections
Badalona, Barcelona, Spain
View Trial DetailsNCT04470648
COVID-19, Coronaviridae Infections
Paris, France
View Trial Details